• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 2
  • 2
  • Tagged with
  • 7
  • 4
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

The molecular pathology, genetic involvement and biochemical characteristics of fused in sarcoma (FUS) protein and chromosome 9p-linked frontotemporal lobar degeneration

Hu, Quan January 2012 (has links)
The fused in sarcoma (FUS) protein has been shown to be a significant disease protein in a subgroup of patients with frontotemporal lobar degeneration (FTLD). Nevertheless, the mechanism underlying FUS associated FTLD is only poorly understood. Recent research has identified a large hexanucleotide repeat expansion in chromosome 9 open reading frame 72 (C9orf72), reinforcing the association between C9orf72 and FTLD. Moreover, an unusual histopathological change has been observed within the granule cell layer of the cerebellum in chromosome 9p-linked frontotemporal dementia with motor neuron disease. Whether this type of cerebellar pathology is a pathological marker for chromosome 9p-linked families remains unknown. The purpose of this study was to genetically, neuropathologically and biochemically characterize FUS and C9orf72 in FTLD, and also to investigate the association between the cerebellar pathology and chromosome 9p-linked families. The genetic sequencing study searching for potential genetic factors of FUS in FTLD failed to detect any pathogenic mutations or variations. Immunohistochemical study for FUS pathology in FTLD provided strong evidence for FUS being the specific pathological protein in all forms of FTLD-FUS. Immunoblotting for FUS in FTLD detected one novel disease-associated FUS aggregate (~37 kDa) in the urea fraction of atypical FTLD with ubiquitinated inclusions (aFTLD-U) frontal cortical samples, suggesting this unique protein product might be more associated with disease than the full-length protein itself. Immunohistochemical study of C9orf72 in FTLD detected a 'synaptic' staining in CA sectors, as the most prominent histological feature identified. Immunoblotting for C9orf72 protein demonstrated no distinctive bands among different diagnostic groups, in frontal and cerebellar cortical regions. The present study also confirmed the presence of cerebellar p62 neuronal cytoplasmic inclusions (NCI) in a proportion of FTLD-TDP cases. Although most of these cases showed an autosomally dominant pattern of inheritance, not all of them shared a common C9orf72 haplotype, or mutation in C9orf72.Much work is still needed to investigate the underlying pathogenesis of FTLD-FUS. Attention should still be given to identifying possible genetic risk factors in FUS using a large series of FTLD samples and searching for other possible proteins within the FUS immunoreactive neuronal inclusions. Moreover, the target protein within the cerebellar p62 NCI remains unknown, but it is clear that it is not C9orf72 protein.
2

The role of Secretory Leukocyte Protease Inhibitor (SLPI) in progranulin regulation and neurodegeneration

Toulson, Gregory January 2013 (has links)
Frontotemporal lobar degeneration (FTLD) is an early onset neurodegenerative disorder which selectively destroys frontal and temporal cortical neurones. The resulting damage leads to a range of language and behavioural deficits, however, episodic memory is generally maintained. Around 10% of FTLD cases are caused by progranulin gene mutations that lead to haploinsufficiency and reduced expression of progranulin. Secretory leukocyte protease inhibitor (SLPI) has been shown to have a key protective effect over progranulin, inhibiting enzymatic cleavage by neutrophil elastase. Previous work demonstrating this role of SLPI is largely from in vitro studies and scenarios with above-physiological SLPI concentrations. To ascertain a role for endogenous SLPI in the regulation of progranulin a murine SLPI knockout model was used and tonic progranulin measurements taken. No change in circulating progranulin levels were seen in SLPI null mice (at 6, 12 or 20 months of age) when compared to non-transgenic controls, though significant differences were observed between male and female SLPI null animals. Similarly, tissue (brain and lung) levels of progranulin were comparable between wild-type and SLPI null mice, despite the presence of active neutrophil elastase. Behavioural analysis of SLPI null mice revealed no major phenotype when compared to wild-type, over a range of behavioural tests. However primary neuronal cultures taken from SLPI null mice did display an elevated progranulin response to bacterial lipopolysaccharide (LPS). These data suggest that, although SLPI may play a role in progranulin regulation during an inflammatory event, it is unlikely to play a major role in progranulin regulation under basal conditions, as reported previously. Therefore under disease conditions regulation of extracellular progranulin is likely through other modulatory factors that have yet to be described.
3

Inhibition of TDP-43 Aggregation using Native State Binding Ligands

Sun, Yulong 19 March 2014 (has links)
TAR DNA binding protein of 43 kDa (TDP-43) has been implicated in the pathogenesis of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Pathologically misfolded and aggregated forms of TDP-43 are found in cytoplasmic inclusion bodies of affected neurons in these diseases. The mechanism by which TDP-43 misfolding causes disease is not well understood. We postulate that the aggregation process plays a major role in pathogenesis, and we hypothesize that oligonucleotide ligands of TDP-43 can stabilize the native functional state of the protein and ameliorate aggregation of this aggregation-prone protein. Using recombinant TDP-43 we were able to examine the extent to which various oligonucleotide molecules affects its aggregation in vitro. We have found that certain natural sequence and de novo designed oligonucleotides bind TDP-43 and prevent its natural tendency to aggregate. The clinical and therapeutic implications of these findings are discussed.
4

Inhibition of TDP-43 Aggregation using Native State Binding Ligands

Sun, Yulong 19 March 2014 (has links)
TAR DNA binding protein of 43 kDa (TDP-43) has been implicated in the pathogenesis of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Pathologically misfolded and aggregated forms of TDP-43 are found in cytoplasmic inclusion bodies of affected neurons in these diseases. The mechanism by which TDP-43 misfolding causes disease is not well understood. We postulate that the aggregation process plays a major role in pathogenesis, and we hypothesize that oligonucleotide ligands of TDP-43 can stabilize the native functional state of the protein and ameliorate aggregation of this aggregation-prone protein. Using recombinant TDP-43 we were able to examine the extent to which various oligonucleotide molecules affects its aggregation in vitro. We have found that certain natural sequence and de novo designed oligonucleotides bind TDP-43 and prevent its natural tendency to aggregate. The clinical and therapeutic implications of these findings are discussed.
5

Troncation conditionnelle de la protéine FUS chez la souris : un nouveau modèle animal du continuum sclérose latérale amyotrophique/démence fronto-temporale / Conditional truncation of the FUS protein in mice : a new animal model of the ALS/FTD continuum

Scekic-Zahirovic, Jelena 11 January 2016 (has links)
La sclérose latérale amyotrophique (SLA) et la démence fronto-temporale (DFT) sont deux maladies qui constituent un continuum clinico-pathologique. La mutation de FUS, une protéine nucléaire à fonctions multiples, provoque des cas familaux de SLA, et ces mutations provoquent une redistribution sub-cellulaire de FUS, du noyau vers le cytoplasme. Certains cas de DFT présentent une telles distribution anormale en l’absence de mutations de FUS. Il n’est pas connu si la maladie est provoquée par une perte de la fonction nucléaire de FUS et/ou un gain de fonction cytoplasmique.Nous avons généré et caractérisé une lignée de souris exprimant une forme cytoplasmique de FUS (Fus-ΔNLS). La localisation exclusive de FUS dans le cytoplasme provoque la mort des motoneurones via un gain de fonction dans les motoneurones eux-mêmes. Une localisation cytoplasmique partielle de FUS est suffisante pour développer un phénotype de la SLA et de DFT. Les mécanismes élucidés permettront de comprendre les bases des SLA/DFT. / Amyotrophic lateral sclerosis (ALS) and Frontotemporal dementia (FTLD) are now considered as a unique clinicopathological spectrum referred to as ALS/FTLD. Cytoplasmic aggregation of the physiologically nuclear FUS protein is a hallmark feature of a subset of ALS/FTLD. It remains unknonwn whether the critical pathogenic event relies on a loss of FUS normal nuclear functions, a toxic gain of function of FUS in the cytoplasm, or a combination of both.To answer this question we have generated a conditional mouse model expressing truncated FUS without nuclear localization signal - FusΔNLS. Our data showed that complete cytoplasmic mislocalization of truncated FUS protein within spinal motor neurons is a major determinant of motor neuron degeneration via toxic gain of function. A partial mislocalization of truncated FUS protein was sufficient to trigger key features of ALS and of FTLD.These studies allowed the elucidation of mechanisms underlying FUS role in ALS/FTLD, and will hopefully lead to development of therapies for these devastating diseases.
6

Fission Yeast as a Model Organism for FUS-Dependent Cytotoxicity in Amyotrophic Lateral Sclerosis

Cone, Alan J. 06 September 2016 (has links)
No description available.
7

The role of chaperone proteins in neurodegenerative diseases

Zhang, Xuekai January 2013 (has links)
Many neurodegenerative diseases are characterized by the accumulation of misfolded proteins that often share common morphological and biochemical features, and can similarly co-localize with several other proteins, including various chaperone proteins. Chaperone proteins, like heat shock protein 27 (HSP27), heme oxygenase 1 (HO-1) and clusterin, have been implicated as potent modulators of misfolded proteins, thus may play important roles in the pathogenesis of neurodegenerative diseases. The present study aims to investigate their roles in the pathogenesis of Frontotemporal lobar degeneration (FTLD), Alzheimer's disease (AD), Parkinson's disease (PD), and Motor neuron disease (MND) by determining their distribution and amount via immunohistochemical staining and western blotting in diseased and control subjects.There were distinct patterns of HSP27 and clusterin immunostaining in different brain regions. For HSP27, patients with AD and FTLD were in general more severely affected than were patients with MND and control subjects. For clusterin, patients with AD and FTLD were more severely affected than control subjects where neurons and glial cells were concerned, while patients with AD and control subjects were more severely affected than those with FTLD where diffuse and cored plaques were concerned. However, there were no obvious differences in the pattern of HO-1 immunostaining in various brain regions in patients with AD or FTLD relative to control subjects. Moreover, there was no association between HSP27, HO-1 and clusterin with disease or histological type, and the ‘classic’ neuropathological changes in FTLD, AD and MND were not immunoreactive to any of these proteins. There were significant correlations between the degrees of HO-1 and clusterin immunostaining in many brain areas for both AD and FTLD cases, and for all cases overall, but none between HSP27 and clusterin or HSP27 and HO-1. Present results suggest an involvement with ongoing cellular stress, misfolded or unfolded protein accumulation or the deficits/failure of other relevant protein quality control systems, in the pathogenesis of these neurodegenerative diseases. Present work may therefore have implications for the further development of ideas concerning the cause or treatment of neurodegenerative diseases where there is aberrant accumulation of misfolded, aggregated protein, and perhaps for conformational diseases in general. However, there are still many issues remain to be elucidated. Further research aimed at understanding the function and mechanisms of the chaperone system, and other protein quality control mechanisms, in the pathogenesis of neurodegenerative diseases is still needed.

Page generated in 0.0461 seconds